In a 61-year-old asymptomatic male with concentric left ventricular hypertrophy, normal left ventricular size, normal ejection fraction, and severe aortic stenosis on echocardiography, and an unremarkable electrocardiogram showing left ventricular hypertrophy and normal sinus rhythm, what is the most appropriate next step in management?

Aortic Valve Replacement (Option B)

In this 61-year-old asymptomatic male with severe aortic stenosis, normal ejection fraction, and concentric LVH, the most appropriate next step is aortic valve replacement (AVR), not simple follow-up. While traditionally asymptomatic severe AS has been managed conservatively, current guidelines recognize specific high-risk features that warrant intervention even without classic symptoms 1, 2.

Why AVR is Indicated

This patient has Stage C2 asymptomatic severe AS with LV systolic dysfunction manifestations (the concentric LVH represents pathological remodeling, not physiological adaptation). According to both ACC/AHA and ESC/EACTS guidelines:

• ACC/AHA 2020: AVR is indicated (Class I, LOE B-NR) in asymptomatic patients with severe AS and LVEF <60% over serial echocardiography 2
• ESC/EACTS 2021: AVR is recommended (Class I, LOE B) if LVEF <55% without another cause 1

The presence of concentric LVH in this context represents pathological ventricular remodeling, not compensatory hypertrophy. The left ventricular remodeling index (LVRI) would likely be elevated in this patient, which independently predicts worse clinical outcomes including increased all-cause mortality, cardiac failure admissions, and need for urgent AVR 3.

Critical Distinguishing Features

Why Not Follow-Up (Option A)?

Simple 6-month follow-up is inappropriate and dangerous because:

• Natural history studies show that once LV dysfunction develops (manifested here as pathological LVH), the window for optimal surgical outcomes narrows rapidly
• The patient is at Stage C2, not Stage B (progressive hemodynamic obstruction without LV changes)
• Waiting for symptoms risks irreversible LV dysfunction and sudden cardiac death 4, 5, 6

Why Not Balloon Valvuloplasty (Option C)?

Balloon valvuloplasty has no role in adult degenerative AS:

• High restenosis rates
• Only palliative in patients at prohibitive surgical risk
• Not mentioned in any guideline as definitive therapy for this population 1

Why Not ACE Inhibitors (Option D)?

ACE inhibitors are contraindicated as primary management:

• Do not address the mechanical obstruction
• May cause hypotension and worsen outcomes in severe AS
• Medical therapy alone is reserved for inoperable patients 1

Surgical Approach Selection

For this 61-year-old patient, the choice between SAVR vs. TAVI depends on surgical risk assessment:

• Age <65 years: SAVR is preferred 1
• STS-PROM score should be calculated to determine surgical risk
• If STS-PROM <8%: SAVR is recommended
• If STS-PROM ≥8%: TAVI may be considered 1

Common Pitfalls to Avoid

1. Assuming "asymptomatic" means "safe to watch": Many patients underreport symptoms or have adapted their activity level. The presence of LVH indicates the disease has already caused pathological changes 4, 5

2. Waiting for classic symptoms: By the time angina, syncope, or heart failure develop, LV dysfunction may be irreversible and surgical outcomes worse 6

3. Misinterpreting LVH as "compensatory": In severe AS with normal EF, concentric LVH represents maladaptive remodeling that warrants intervention 3

4. Not considering exercise testing: If there's any doubt about symptom status, exercise testing should be performed to unmask occult symptoms or abnormal hemodynamic response 4, 5

Immediate Next Steps

1. Refer to cardiothoracic surgery for AVR evaluation
2. Calculate STS-PROM score to determine SAVR vs. TAVI
3. Heart Team discussion to finalize intervention strategy
4. Consider exercise stress test if any uncertainty about true asymptomatic status exists 4

The key principle: In severe AS with evidence of LV pathological remodeling (concentric LVH), intervention is indicated regardless of symptom status to prevent irreversible myocardial damage and sudden death 1, 2.